B. Riley Issues Pessimistic Forecast for Lantheus Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Analysts at B. Riley cut their Q3 2025 earnings estimates for Lantheus in a research report issued on Thursday, March 20th. B. Riley analyst Y. Zhi now expects that the medical equipment provider will post earnings per share of $1.51 for the quarter, down from their prior forecast of $1.57. B. Riley currently has a “Buy” rating and a $122.00 target price on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share.

Several other brokerages also recently commented on LNTH. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Stock Performance

NASDAQ LNTH opened at $99.77 on Monday. The stock has a 50-day simple moving average of $92.91 and a 200 day simple moving average of $96.45. Lantheus has a twelve month low of $57.92 and a twelve month high of $126.89. The stock has a market capitalization of $6.83 billion, a PE ratio of 16.60 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock worth $6,110,806 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its holdings in Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after acquiring an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after acquiring an additional 435,445 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Lantheus in the 4th quarter worth approximately $36,183,000. Finally, Groupama Asset Managment bought a new stake in Lantheus during the 3rd quarter worth approximately $439,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.